Drugs / Indole-3-carbinol
Indole-3-carbinol
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03687073 | Nov 2018 → May 2021 | — | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT00100958 | Nov 2004 → ? | cancer of unknown primary site | University of Kansas | Completed | No outcome recorded |
| Phase 1 | NCT00033345 | Jan 2002 → Jul 2008 | breast cancer | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07709533 | Jul 2026 → Jun 2029 expected | — | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07164183 | Sep 2025 → Oct 2026 expected | endometriosis | Alcea | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00607932 | Mar 2005 → Jan 2007 | prostate cancer | Vanderbilt University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Indole-3-carbinol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709533 ↗ |
| Known as | Indinol Forto | “Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks” NCT07164183 ↗ |
| Known as | indolecarbinol | “Indinol Forto (indolecarbinol (indole-3-carbinol)) 200 mg capsules orally twice a day during 24 weeks” NCT07164183 ↗ |
| Known as | NSC-525801 | ChEMBL registry synonym — accepted as the source's own label CHEMBL155625 ↗ |
| Modality | Small molecule | — CHEMBL155625 ↗ |
| Route | Oral | “oral indole-3-carbinol” NCT00033345 ↗ |